Shuttle Pharmaceuticals (SHPH) said late Thursday it filed a provisional US patent for prostate-specific membrane antigen ligand conjugates to treat prostrate cancer.
The patent, "PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy," could advance diagnostic and therapeutic programs for patients with metastatic castration-resistant prostate cancer, the company said.
PSMA is expressed on the surface of cancer cells, and ligands targeting the antigen are smaller and present potential advantages for more efficient drug delivery, according to a company statement.
Shares are up nearly 10% in after-hours activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。